FGF2 Gene Expression Assays for Depression Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating mental disorders, such as major depression and bipolar disorders, are inadequate due to a lack of reliable biomarkers and the ineffectiveness of existing treatments, which often lead to misdiagnosis and undesirable side effects.
Innovation Solution
The use of FGF2 polypeptide for chronic administration and novel assays to diagnose mental illnesses by detecting gene expression levels associated with mental disorders, including the correlation of FGFR2 splice variants with major depressive disorder, and the administration of compounds targeting specific genes to treat symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for mental disorders, then diagnosis can be performed, but accuracy is low leading to misdiagnosis
Solution Approach 1:
The patent replaces conventional clinical diagnostic methods (mechanical/subjective assessment) with gene expression analysis (molecular/biochemical analysis). By measuring mRNA levels of specific genes (BDNF, SLC6A4, HTR2A, DRD2, CACNA1C) in blood samples, the invention provides an objective, quantifiable diagnostic approach that substitutes subjective clinical judgment with precise molecular measurement, thereby improving both accuracy and reliability of diagnosis.
2Reliability
If antidepressants are administered to treat depression, then treatment can be provided, but side effects occur including metabolic syndrome, sexual dysfunction, and weight gain
Solution Approach 1:
The patent enables self-service in treatment selection by using the patient's own gene expression profile to determine the most appropriate treatment. By analyzing the patient's genetic makeup (BDNF Val66Met polymorphism, SLC6A4 5-HTTLPR polymorphism, etc.), the system allows the patient to receive personalized treatment recommendations without trial-and-error prescribing, thereby avoiding the side effects associated with ineffective medications while maintaining treatment efficacy.
Solution Approach 2:
The patent changes the treatment approach from a one-size-fits-all model to a personalized model based on genetic parameters. By measuring specific gene expression levels and genetic polymorphisms, the invention transforms treatment selection into a parameter-driven process where treatment decisions are based on quantitative genetic data rather than empirical trial-and-error, thereby reducing exposure to medications that cause harmful side effects.
3Measurement precision
If gene expression analysis is performed to improve diagnosis accuracy, then diagnostic precision improves, but complexity of the diagnostic process increases
Solution Approach 1:
The patent segments the complex diagnostic process into distinct, manageable components: (1) collecting blood samples, (2) extracting RNA, (3) measuring expression of specific genes (BDNF, SLC6A4, HTR2A, DRD2, CACNA1C), and (4) interpreting results according to established criteria. This segmentation transforms a potentially overwhelming complex analysis into a series of simple, standardized steps that can be performed using routine laboratory techniques, thereby reducing perceived complexity while maintaining high diagnostic precision.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness.